MK-677, also known as ibutamoren, is a non-peptide orally active growth hormone secretagogue that mimics ghrelin signaling at the GHS-R1a receptor. Its oral bioavailability and long duration of action distinguish it from injectable peptide GH secretagogues.
Pharmacological Profile
MK-677 is a spiroindoline sulfonamide compound that acts as a potent, selective agonist of the ghrelin receptor. Unlike peptide-based GH secretagogues, MK-677 is orally bioavailable with an approximate half-life of 4-6 hours and sustained GH-elevating effects lasting up to 24 hours due to its influence on pulsatile GH secretion patterns. It increases GH secretion by amplifying GH pulse amplitude without significantly altering pulse frequency. MK-677 does not suppress the hypothalamic-pituitary-adrenal axis and produces sustained IGF-1 elevation with chronic administration. The compound’s non-peptide structure makes it resistant to gastrointestinal degradation, enabling consistent oral dosing in research protocols.
Research Applications and Findings
Long-term studies spanning up to two years demonstrate that MK-677 produces sustained increases in IGF-1 and GH levels without tachyphylaxis, a notable advantage over injectable GHRP peptides. Body composition research shows increased lean body mass and transient increases in basal metabolic rate. Bone mineral density studies in elderly populations reveal improvements in osteoblast markers and femoral neck BMD with extended administration. Sleep architecture research indicates enhanced slow-wave sleep duration, consistent with GH’s role in deep sleep regulation. MK-677 increases appetite through central ghrelin receptor activation, which is a significant variable in metabolic research protocols. Studies on nitrogen balance show improved nitrogen retention, suggesting anabolic potential in catabolic states. Glucose metabolism research requires careful monitoring, as MK-677 may decrease insulin sensitivity during the initial weeks of administration, though this effect often attenuates with continued use.
Frequently Asked Questions
How does MK-677 differ from injectable GH secretagogues?
MK-677’s oral bioavailability and extended duration of action eliminate the need for injection-based protocols. It produces more sustained GH/IGF-1 elevation compared to the acute peaks seen with GHRP injections. However, its non-selective ghrelin receptor activation produces appetite stimulation and potential insulin sensitivity changes that are less prominent with selective peptides like ipamorelin.
Does MK-677 show desensitization like GHRP peptides?
Research consistently shows that MK-677 maintains its GH-releasing efficacy over extended periods of 6-24 months without significant desensitization. This sustained activity likely reflects its pharmacokinetic profile and continuous receptor engagement pattern rather than the pulsatile stimulation of injectable GHRPs.